Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a protein considered as a promising candidate for treatment owing to its selective apoptotic effect on cancer cells [8,9], is not therapeutically effective, as IV administration leads to insufficient amount at the target site due to rapid degradation in vivo. The gene discussed is TNFSF10; the disease is cancer.